The Europe deep brain stimulation device market size was estimated at USD 440 million in 2025 and is projected to be worth around USD 1,194.20 million by 2035, is projected to expand at a CAGR of 10.50% from 2026 to 2035. The growing elderly population and increasing neurodegenerative disease cases are driving the demand for the deep brain stimulation device market.

Europe Deep Brain Stimulation Devices Market Statical Scope

The European deep brain stimulation device market is significantly growing due to the increasing prevalence of neurodegenerative diseases and the rising ageing population across the region. Countries such as Germany, France, and the United Kingdom are investing heavily in advanced neurology care and minimally invasive surgical technologies. The rising awareness among physicians and patients regarding long term symptoms management through DBS therapy is driving procedural adoption across the European Union.

European healthcare systems are encouraging research collaborations to improve stimulation accuracy, battery efficiency, and patient monitoring capabilities. The growing transformative trend in the region includes advancements in neurotechnology , increased adoption of minimally invasive procedures, and integration of artificial intelligence , which are reshaping the industry.

Europe Deep Brain Stimulation Devices Market Share, By Product Outlook, 2025, (%)

• Single Channel DBS - Single Channel DBS leads the segment, with a share of 32%, driven by earlier adoption, simpler configuration, and cost-effective treatment options.
• Dual Channel DBS - Dual Channel DBS hold a significant portion, with a share of 68%, supported by higher clinical precision, improved symptom control, and increasing preference for advanced bilateral stimulation systems.

Europe Deep Brain Stimulation Devices Market Share, By Application outlook, 2025, (%)

• Pain Management - Pain Management leads the segment, with a share of 18%, driven by growing use of neuromodulation therapies for chronic pain conditions.
• Epilepsy - Epilepsy holds a significant portion, with a share of 27%, supported by the rising adoption of deep brain stimulation in drug-resistant epilepsy cases.
• Essential Tremor - Essential Tremor accounts for 55%, driven by high prevalence and strong therapeutic effectiveness of DBS in tremor control.

Europe Deep Brain Stimulation Devices Market Share, By End Use Outlook, 2025, (%)

• Hospitals - Hospitals lead the segment, with a share of 70%, driven by advanced neurosurgical infrastructure, high procedure volumes, integrated neurology departments and a government supported healthcare system.
• Neurology Clinics - Neurology Clinics hold a significant portion, with a share of 15%, supported by specialized neurological care, follow-up treatment services, and patient centred neurological care.
• Ambulatory Surgical Centers - Ambulatory Surgical Centers account for 10%, driven by increasing minimally invasive surgical procedures, increasing healthcare cost pressures and growing demand for efficient outpatient neurological care.
• Research Centers - Research Centers hold 5%, supported by a strong European funded research program that focuses on precision neuromodulation and improved DBS targeting technologies.

Recent Developments in the Market

• In March 2025, Newronika is preparing for the launch of AlphaDBS this year in Europe. AlphaDBS is a next generation adaptive deep brain stimulation (DBS) system used for treating Parkinson's disease. The company received CE marking for AlphaDBS, which is required for products to be sold commercially in the European Union. AlphaDBS monitors patients' brain activity and adjusts stimulation based on real time feedback. Compared to conventional DBS systems, this offers personalized stimulation.
• In April 2026, Medtronic plc, a global leader in healthcare technology, received CE mark approval for its Stealth AXiS surgical system for spine and cranial procedures. This allows the launch of Stealth AXiS in the European Union. This launch helps in the expansion of the company's portfolio internationally and supports growth in spine, cranial surgery and neurostimulation sectors.

Competitive Landscape

• The competitive landscape of the European deep brain stimulation device market includes several key players, such as Medtronic, Boston Scientific, Abbott, Beijing Pins, SceneRay, Boston Scientific Corporation, Fisher Wallace, ALEVA NEUROTHERAPEUTICS SA, Deep Brain Innovations, LLC, St. Jude Children's Research Hospital, Stanford Health Care, NeuroPace Inc., Renishaw plc., and Functional Neuromodulation Ltd.
• Medtronic is a pioneer in the medical device industry and maintains a strong position in the DBS market. To maintain a strong position, its strategies include continuous innovation in device technology and expanding patient access through partnerships.
• Boston Scientific hold a significant share of the deep brain stimulation device market in the European market. The company focuses on expanding its product line and investing in research and development to grow in the market.
• Beijing Pins and SceneRay are emerging players in the market, focusing on delivering cost effective solutions and leveraging advanced imaging technologies to enhance DBS efficacy.

Segment Covered in the Report

By Product

• Single Channel
• Dual Channel

By Application

• Pain Management
• Epilepsy
• Essential Tremor
• Obsessive-compulsive Disorders (OCD)
• Depression
• Dystonia
• Parkinson's Disease
• Others

By End-use

• Hospitals
• Neurology Clinics
• Ambulatory Surgical Centers
• Research Centers